☆ 4.7 Article

Bruceine A: Suppressing metastasis via MEK/ERK pathway and invoking mitochondrial apoptosis in triple-negative breast cancer

BIOMEDICINE & PHARMACOTHERAPY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Pharmacology & Pharmacy

Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer

Luca Boscolo Bielo et al.

Summary: Triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer with unfavorable outcomes, traditionally had limited systemic treatment options. However, novel drugs have been approved and are causing economic challenges due to their high prices.

EXPERT OPINION ON PHARMACOTHERAPY (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Bruceine a exerts antitumor effect against colon cancer by accumulating ROS and suppressing PI3K/Akt pathway

Chaozheng Zhang et al.

Summary: Bruceine A (BA), derived from Bruceine javanica, displays multiple biological activities and regulates various intracellular signal transduction pathways. However, its pharmacological mechanism in treating colon cancer (CC) remains unclear. In this study, BA was found to exhibit anticancer effects on CC cells by targeting the Akt1 and Jun as well as the PI3K/Akt pathway. Additionally, BA inhibited cell cycle progression, promoted apoptosis, and suppressed cell migration in CC cells. These findings suggest that BA has the potential to be a promising chemotherapy drug for the treatment of CC.

FRONTIERS IN PHARMACOLOGY (2023)

添加到收藏夹

Article Urology & Nephrology

Bruceine A protects against diabetic kidney disease via inhibiting galectin-1

Huiying Li et al.

Summary: Research has found that Bruceine A is a protective molecule against diabetic kidney disease, with the ability to inhibit inflammatory signal transduction mediated by galectin-1, providing a novel pharmacological therapeutic approach.

KIDNEY INTERNATIONAL (2022)

添加到收藏夹

Article Plant Sciences

Activation of mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway by voacamine suppress breast cancer progression

Yi Zuo et al.

Summary: This study investigated the anti-cancer effects of VOA on breast cancer cells and elucidated the underlying mechanisms, including activation of mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway. Additionally, VOA significantly reduced tumor size without causing apparent toxicity.

PHYTOMEDICINE (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Voacamine is a novel inhibitor of EGFR exerting oncogenic activity against colorectal cancer through the mitochondrial pathway

Yao Chen et al.

Summary: This study evaluated the anticancer efficacy and mechanisms of a novel natural product called Voacamine (VOA) against colorectal cancer (CRC). The results showed that VOA could suppress cell proliferation and migration, promote cell apoptosis, and affect mitochondrial function. Further investigations revealed that VOA exerted its anticancer effects by inhibiting the EGFR/PI3K/Akt pathway. Animal experiments also supported the potential of VOA as a therapeutic agent for treating CRC. This study provides evidence for the use of VOA as a potential drug in the treatment of CRC.

PHARMACOLOGICAL RESEARCH (2022)

添加到收藏夹

Article Cell Biology

Implication of human endogenous retrovirus W family envelope in hepatocellular carcinoma promotes MEK/ERK-mediated metastatic invasiveness and doxorubicin resistance

Yan Zhou et al.

Summary: Our study revealed that Syncytin-1 expression is up-regulated in HCC, particularly in advanced stages, and can serve as a predictor of patient prognosis. Furthermore, detailed analysis showed a significant association between Syncytin-1 and HBsAg positivity in HCC patients, suggesting a key role in the development and treatment of HCC.

CELL DEATH DISCOVERY (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Nanoparticle-delivered miriplatin ultrasmall dots suppress triple negative breast cancer lung metastasis by targeting circulating tumor cells

Yunfei Li et al.

Summary: The study developed a novel ultrasmall Pt(II) dot that displayed superior DNA damage capability and significantly reduced the CSC-like properties of TNBC cells, as well as targeted circulating tumor cells in vivo to suppress breast cancer metastasis. The ultrasmall Pt(II) dots represent a promising therapeutic agent for reducing cancer metastasis through metal-based nanomedicines.

JOURNAL OF CONTROLLED RELEASE (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Bruceine A induces cell growth inhibition and apoptosis through PFKFB4/GSK3β signaling in pancreatic cancer

Pengfei Zhang et al.

Summary: Bruceine A exhibits strong anti-tumor activity against human pancreatic cancer cells in vitro and in vivo by targeting PFKFB4 and its downstream target GSK3 beta to inhibit glycolysis, thereby inducing cell growth inhibition and apoptosis. This suggests that bruceine A may serve as a potent agent for treating human pancreatic cancer.

PHARMACOLOGICAL RESEARCH (2021)

添加到收藏夹

Article Medicine, Research & Experimental

EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer

Xia Liu et al.

Summary: Research has shown that inhibiting EGFR can block the circulating cancer stem cell (cCSC) clustering and lung metastasis of triple-negative breast cancer (TNBC). In addition to CD44, microRNA-30c also plays a negative regulatory role in cCSC clustering and lung metastasis.

THERANOSTICS (2021)

添加到收藏夹

Article Engineering, Biomedical

Calcitriol-Loaded Dual-pH-Sensitive Micelle Counteracts Pro-Metastasis Effect of Paclitaxel in Triple-Negative Breast Cancer Therapy

Zhong Zheng et al.

ADVANCED HEALTHCARE MATERIALS (2020)

添加到收藏夹

Review Oncology

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

Antonio Marra et al.

NPJ BREAST CANCER (2020)

添加到收藏夹

Article Oncology

MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: implication of Wnt/catenin beta and MEK/ERK signaling pathways

Ruitao Zhang et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Article Oncology

MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells

Sangmin Kim et al.

TUMOR BIOLOGY (2016)

添加到收藏夹

Article Oncology

MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model

Chandra Bartholomeusz et al.

MOLECULAR CANCER THERAPEUTICS (2015)

添加到收藏夹

Article Oncology

Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma

Federica Catalanotti et al.

CLINICAL CANCER RESEARCH (2013)

添加到收藏夹

Article Veterinary Sciences

Evaluation of Efficacy of Bruceine A, a Natural Quassinoid Compound Extracted from a Medicinal Plant, Brucea javanica, for Canine Babesiosis

Ryo Nakao et al.

JOURNAL OF VETERINARY MEDICAL SCIENCE (2009)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

P. J. Roberts et al.

ONCOGENE (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.